(NYSE: PEN) Penumbra's forecast annual revenue growth rate of 13.62% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.04%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.29%.
Penumbra's revenue in 2026 is $1,403,665,000.On average, 22 Wall Street analysts forecast PEN's revenue for 2026 to be $62,945,857,012, with the lowest PEN revenue forecast at $59,610,197,507, and the highest PEN revenue forecast at $67,184,106,736. On average, 20 Wall Street analysts forecast PEN's revenue for 2027 to be $71,500,842,566, with the lowest PEN revenue forecast at $66,791,676,206, and the highest PEN revenue forecast at $76,523,953,350.
In 2028, PEN is forecast to generate $81,076,147,498 in revenue, with the lowest revenue forecast at $74,640,286,806 and the highest revenue forecast at $86,138,501,335.